Biased agonism of G protein-coupled receptors as a novel strategy for osteoarthritis therapy

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Osteoarthritis (OA) is a degenerative joint disease causing pain and cartilage loss, with current treatments offering only symptom relief.
• G protein-coupled receptors (GPCRs) are key regulators of OA pathogenesis, but their complex signaling pathways complicate targeted therapies.
• Biased agonism, which selectively activates specific GPCR pathways, presents a promising strategy to enhance therapeutic efficacy and minimize side effects.

Purpose of the Study:

• To review the role of biased signaling in OA-associated GPCRs.
• To explore potential biased agonists, including those in clinical trials and natural products from Traditional Chinese Medicine (TCM).
• To highlight the therapeutic potential of biased agonism for developing targeted OA treatments.

Main Methods:

• Literature review of biased signaling in OA-related GPCRs.
• Analysis of ligands currently in clinical trials for OA.
• Exploration of Traditional Chinese Medicine compounds as potential biased agonists.

Main Results:

• Identified several key OA-associated GPCRs involved in inflammation, chondrocyte survival, and matrix homeostasis.
• Examined various ligands, including those in clinical development and natural products, as potential biased agonists.
• Highlighted the diverse structures and bioactivities of TCM compounds as novel therapeutic candidates.

Conclusions:

• Biased agonism represents a promising strategy for developing targeted and safer osteoarthritis therapies.
• Selective targeting of GPCR pathways can address the complex pathology of OA more effectively.
• Integrating molecular insights with clinical translation, particularly through natural products, offers new avenues for OA treatment.